Biomarker profiling of plasma samples utilizing RANDOX biochip array technology

Saluk, Jennifer; Hoppensteadt, Debra; Syed, Danyel; Liles, Jeffrey; Abro, Schuharazad; Walborn, Amanda; Bansal, Vinod; Fareed, Jawed

doi:10.23736/s0392-9590.17.03854-8

Cited by 10 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic Syndrome Array I was used to measure Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), insulin, leptin, ferritin, resistin and Plasminogen Activator Inhibitor-1 (PAI-1), while the Metabolic Syndrome Array II was used to examine adiponectin, C-reactive Protein (CRP) and cystatin-C, following the procedures instructed by the manufacturer. Further details of the assays are reported elsewhere [ 100 , 108 , 109 , 110 , 111 ]; however, we have outlined the details as follows.…”

Section: Methodsmentioning

confidence: 99%

“…Similarly, potential advance MetS biomarkers can provide means for early detection and management of the syndrome and its subsequent complications amongst older patients and for risk stratification in aging populations. Within the recent years, modern and innovative clinical chemistry assays such as multiplex analysis via Luminex-100 [ 99 ] or Biochip Array Technology via Evidence Investigator [ 100 ] have been developed for the assessment and profiling of the advance biomarkers of MetS, confirming the potential and opportunities for assessment, diagnosis and early detection of the risk markers.…”

Section: Introductionmentioning

confidence: 99%

“…For instance, the enzyme-linked immunosorbent assay (ELISA), which is the most established clinical chemistry assay for the analysis of these markers, is expensive and requires laboratory expertise. The ELISA kits for the analysis of a single biomarker can cost USD 500–1000 and this is adequate for the analysis of 40 patient samples, while duplicate running of each patient samples is recommended for accurate assessment, limiting the wide use of the method as a cost-effective solution for the analysis of multiple biomarkers within large cohorts of participants and clinical trials [ 100 ]. The use of the multiplex analysis such as biochip array technology is also barely more affordable as it requires expensive research equipment and biochip (biochip immune-analyzer costing > USD 50,000 and biomarkers kits costing an average of USD 5000, which is adequate for the assessment of 43 patient samples and 9 calibrators [ 100 ]).…”

Section: Introductionmentioning

confidence: 99%

“…The ELISA kits for the analysis of a single biomarker can cost USD 500–1000 and this is adequate for the analysis of 40 patient samples, while duplicate running of each patient samples is recommended for accurate assessment, limiting the wide use of the method as a cost-effective solution for the analysis of multiple biomarkers within large cohorts of participants and clinical trials [ 100 ]. The use of the multiplex analysis such as biochip array technology is also barely more affordable as it requires expensive research equipment and biochip (biochip immune-analyzer costing > USD 50,000 and biomarkers kits costing an average of USD 5000, which is adequate for the assessment of 43 patient samples and 9 calibrators [ 100 ]). Secondly, the direct association between the biomarkers and MetS and the potential predictive power of the individual circulatory markers in the early detection of the cardiometabolic risk have yet to be fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study)

et al. 2021

View full text Add to dashboard Cite

Background: Metabolic Syndrome (MetS) is a cluster of risk factors for diabetes and cardiovascular diseases with pathophysiology strongly linked to aging. A range of circulatory metabolic biomarkers such as inflammatory adipokines have been associated with MetS; however, the diagnostic power of these markers as MetS risk correlates in elderly has yet to be elucidated. This cross-sectional study investigated the diagnostic power of circulatory metabolic biomarkers as MetS risk correlates in older adults. Methods: Hundred community dwelling older adults (mean age: 68.7 years) were recruited in a study, where their blood pressure, body composition and Pulse Wave Velocity (PWV) were measured; and their fasting capillary and venous blood were collected. The components of the MetS; and the serum concentrations of Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), Plasminogen Activator Inhibitor-I (PAI-I), Leptin, Adiponectin, Resistin, Cystatin-C, C-Reactive Protein (CRP), insulin and ferritin were measured within the laboratory, and the HOMA1-IR and Atherogenic Index of Plasma (AIP) were calculated. Results: Apart from other markers which were related with some cardiometabolic (CM) risk, after Bonferroni correction insulin had significant association with all components of Mets and AIP. These associations also remained significant in multivariate regression. The multivariate odds ratio (OR with 95% confidence interval (CI)) showed a statistically significant association between IL-6 (OR: 1.32 (1.06–1.64)), TNF-α (OR: 1.37 (1.02–1.84)), Resistin (OR: 1.27 (1.04–1.54)) and CRP (OR: 1.29 (1.09–1.54)) with MetS risk; however, these associations were not found when the model was adjusted for age, dietary intake and adiposity. In unadjusted models, insulin was consistently statistically associated with at least two CM risk factors (OR: 1.33 (1.16–1.53)) and MetS risk (OR: 1.24 (1.12–1.37)) and in adjusted models it was found to be associated with at least two CM risk factors and MetS risk (OR: 1.87 (1.24–2.83) and OR: 1.25 (1.09–1.43)) respectively. Area under curve (AUC) for receiver operating characteristics (ROC) demonstrated a good discriminatory diagnostics power of insulin with AUC: 0.775 (0.683–0.866) and 0.785 by cross validation and bootstrapping samples for at least two CM risk factors and AUC: 0.773 (0.653–0.893) and 0.783 by cross validation and bootstrapping samples for MetS risk. This was superior to all other AUC reported from the ROC analysis of other biomarkers. Area under precision-recall curve for insulin was also superior to all other markers (0.839 and 0.586 for at least two CM risk factors and MetS, respectively). Conclusion: Fasting serum insulin concentration was statistically linked with MetS and its risk, and this link is stronger than all other biomarkers. Our ROC analysis confirmed the discriminatory diagnostic power of insulin as CM and MetS risk correlate in older adults.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The individual FA composition was expressed as a weight percentage of the total FFAs (presented as %). The levels of markers affecting insulin resistance (resistin, leptin), plasminogen activator inhibitor 1 (PAI-1), and insulin levels were measured by biochip array technology using chemiluminescent sandwich immunoassays (Metabolic Syndrome Array I, Randox, Crumlin, UK) that were applied to the evidence investigator analyzer [13]. For quality control in the monitoring of the accuracy and precision control assays (Metabolic Syndrome Multianalyte Controls), EV3757 was used.…”

Section: Blood Collection and Sample Analysismentioning

confidence: 99%

The Impact of Glucose-Based or Lipid-Based Total Parenteral Nutrition on the Free Fatty Acids Profile in Critically Ill Patients

et al. 2020

View full text Add to dashboard Cite

Introduction: Our study aim was to assess how the macronutrient intake during total parenteral nutrition (TPN) modulates plasma total free fatty acids (FFAs) levels and individual fatty acids in critically ill patients. Method: Adult patients aged 18–80, admitted to the intensive care unit (ICU), who were indicated for TPN, with an expected duration of more than three days, were included in the study. Isoenergetic and isonitrogenous TPN solutions were given with a major non-protein energy source, which was glucose (group G) or glucose and lipid emulsions (Smof lipid; group L). Blood samples were collected on days 0, 1, 3, 6, 9, 14, and 28. Results: A significant decrease (p < 0.001) in total FFAs occurred in both groups with a bigger decrease in group G (p < 0.001) from day 0 (0.41 ± 0.19 mmol∙L−1) to day 28 (0.10 ± 0.07 mmol∙L−1). Increased palmitooleic acid and decreased linoleic and docosahexaenoic acids, with a trend of increased mead acid to arachidonic acid ratio, on day 28 were observed in group G in comparison with group L. Group G had an insignificant increase in leptin with no differences in the concentrations of vitamin E, triacylglycerides, and plasminogen activator inhibitor-1. Conclusion: Decreased plasma FFA in critically ill patients who receive TPN may result from increased insulin sensitivity with a better effect in group G, owing to higher insulin and glucose dosing and no lipid emulsions. It is advisable to include a lipid emulsion at the latest from three weeks of TPN to prevent essential fatty acid deficiency.

show abstract

Leucine‐enriched whey protein supplementation, resistance‐based exercise, and cardiometabolic health in older adults: a randomized controlled trial

Kirk

Mooney

Vogrin

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Increasing protein intake (above the Recommended Dietary Amount) alone or with resistance-based exercise is suggested to improve cardiometabolic health; however, randomized controlled trials (RCTs) are needed to confirm this. Methods The Liverpool Hope University-Sarcopenia Aging Trial (LHU-SAT) was a 16 week RCT (ClinicalTrials.gov Identifier: NCT02912130) of 100 community-dwelling older adults [mean age: 68.73 ± 5.80 years, body mass index: 27.06 ± 5.18 kg/m 2 (52% women)] who were randomized to four independent groups [Control (C), Exercise (E), Exercise + Protein (EP), Protein (P)]. E and EP completed supervised and progressive resistance-based exercise (resistance exercise: two times per week, functional circuit exercise: once per week), while EP and P were supplemented with a leucine-enriched whey protein drink (three times per day) based on individual body weight (0.50 g/kg/meal, 1.50 g/kg/day). Outcome measures including arterial stiffness (pulse wave velocity), fasting plasma/serum biomarkers [glucose/glycated haemoglobin, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein, insulin, resistin, leptin, adiponectin, C-reactive protein, tumour necrosis factor-alpha, interleukin-6, cystatin-C, & ferritin], insulin resistance (HOMA-IR), and kidney function (eGFR) were measured before and after intervention. Results Total protein intake (habitual diet plus supplementation) increased to 1.55 ± 0.69 g/kg/day in EP and to 1.93 ± 0.72 g/kg/day in P, and remained significantly lower (P < 0.001) in unsupplemented groups (E: 1.08 ± 0.33 g/kg/day, C: 1.00 ± 0.26 g/kg/day). At 16 weeks, there was a group-by-time interaction whereby absolute changes in LDL-cholesterol were lower in EP [mean difference: À0.

show abstract

Biomarker profiling of plasma samples utilizing RANDOX biochip array technology

Cited by 10 publications

References 22 publications

Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study)

Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study)

The Impact of Glucose-Based or Lipid-Based Total Parenteral Nutrition on the Free Fatty Acids Profile in Critically Ill Patients

Leucine‐enriched whey protein supplementation, resistance‐based exercise, and cardiometabolic health in older adults: a randomized controlled trial

Contact Info

Product

Resources

About